Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report

Figure 1 Circulating plasma cells as evident on the peripheral smear (1000 ×) in June 2015.

Figure 2 Flow-cytometry analysis. A: Plasma cells (PCs) in the peripheral blood at the time of diagnosis (here exemplarily shown CD38 and CD138); B: PCs in the peripheral blood before venetoclax use; C: PCs in the bone marrow after two cycles of venetoclax.

Figure 3 Hematoxylin and eosin staining and immunohistostaining of bone marrow clot section (400 ×). H/E: Hematoxylin and eosin staining.

Figure 4 Fluorescence in situ hybridization analysis. A: RB1 (13q14) gene deletion in fluorescence in situ hybridization; B: CKS1B (1q21) gene amplification in fluorescence in situ hybridization.